Semax: a complete guide to the ACTH analog nootropic

Semax is a synthetic peptide built from seven amino acids: Met-Glu-His-Phe-Pro-Gly-Pro ^[1]. Russian neuropharmacologists at the Institute of Molecular Genetics designed it in the late 1980s. They took the active core of adrenocorticotropic hormone (the fragment ACTH 4-7, which is Met-Glu-His-Phe) and tacked on a proline-glycine-proline tail to slow enzymatic breakdown ^[2].

The design choice mattered. Endogenous ACTH drives cortisol release through the adrenal cortex, which is useful biology in the wrong context and counterproductive if what you want is a clean neurotrophic effect. The Russian team kept the part of ACTH that talks to the central nervous system and engineered out the part that triggers steroidogenesis. What's left is, in theory, a neuropeptide that hits melanocortin-adjacent targets without the hormonal tail wagging the dog.

It was first described in the scientific literature in the early 1990s, and by the 1990s it was a registered prescription drug in Russia.

Outside Russia and a handful of CIS states, Semax has no approved indication anywhere. The FDA has never evaluated it. The EMA has never evaluated it. That asymmetry, three decades of clinical use on one side of a border and zero regulatory engagement on the other, is the central fact every researcher needs to hold in mind.

Semax's mechanism is, to use the honest phrase, incompletely characterized. The Wikipedia entry says so. The primary literature says so. What we have is a handful of mechanistic threads, some better supported than others.

The thread with the most evidence runs through BDNF and NGF. In rat models, a single intranasal dose significantly upregulates Bdnf and Ngf gene expression in the hippocampus and frontal cortex within minutes (PMID 18756821). BDNF, once released, signals through the TrkB receptor and supports neuronal survival and synaptic plasticity, the kind of slow structural change that gets called neuroplasticity. If Semax does anything cognitively meaningful, this is the most likely chemical reason why.

A second thread runs through monoamines. Eremin and colleagues used microdialysis to track what happens in the rat striatum after Semax. Serotonin turnover climbed, with 5-HIAA levels rising substantially in the hours following administration, and Semax potentiated amphetamine-induced dopamine release without lifting baseline dopamine on its own ^[3]. Read carefully, that's a modulator, not a stimulant in the classical sense.

The other threads are thinner. Enkephalinase inhibition is proposed, which would prolong endogenous opioid peptide activity. A 2025 mouse study identified the μ-opioid receptor gene Oprm1 as a target relevant to spinal cord injury recovery (PMID 40692165) ^[4]. In vitro work shows Semax interferes with copper-induced amyloid-β aggregation (PMID 35080861) ^[5], which is intriguing for Alzheimer's pathology but a long way from clinical relevance. Transcriptomic data from ischemic rat brains hint at transthyretin upregulation as one downstream neuroprotective mechanism ^[6].

Half-life is short. Standard Semax peaks in effect at two to four hours before peptidases in the nasal mucosa and blood chew it apart. The acetylated and amidated variants extend that to four to eight hours by blocking the enzymes that attack the molecule's ends.

Route matters a lot. Intranasal delivery partially bypasses the blood-brain barrier through olfactory nerve pathways, which is why nearly every Russian clinical protocol uses a nasal spray.

Here is where Semax marketing tends to outrun the data, so it's worth being precise.

The strongest BDNF finding is the 2008 rat study (PMID 18756821) showing real Bdnf and Ngf gene expression increases in hippocampus and frontal cortex within twenty minutes of a single intranasal dose. The dose, 50 mg/kg in a rat, doesn't translate directly to human dosing, but the signal of rapid, regionally specific upregulation of two neurotrophic factors is real.

What this doesn't tell you: how often that translates into measurable cognitive change in humans, how long the effect persists with repeated dosing, whether tolerance develops, or whether the BDNF protein actually reaches functional levels at the synapses where it would matter.

One human study did measure plasma BDNF. Gusev and Martynov's 2018 stroke trial reported elevated plasma BDNF in patients receiving intranasal treatment across two ten-day courses. Plasma BDNF is an imperfect proxy for central BDNF, and the trial was neither randomized nor placebo-controlled. Take the signal, discount it appropriately.

The honest read: BDNF upregulation is the best-supported piece of the Semax mechanism story. It's also still an animal-model story with a thin human bridge.

Stroke is the indication Russian neurology takes Semax most seriously for. The studies, taken at face value, look encouraging. Examined for rigor, they look like what they are: regional clinical evidence that hasn't been stress-tested by independent Western trials.

The 1997 Gusev study enrolled 30 patients with acute hemispheric ischemic stroke, gave them Semax at 12 to 18 mg/day for five to ten days, and compared outcomes to 80 historical controls on conventional therapy ^[7]. The Semax group recovered faster, particularly on motor measures. The design, non-randomized with historical controls and no blinding, wouldn't get past peer review at a Western stroke journal today.

The 2018 follow-up was larger and more careful. Around 110 patients, multiple courses of intranasal Semax at 6,000 mcg/day, with assessments at several points post-stroke. Plasma BDNF rose. Barthel index scores (a measure of functional independence) improved. MRC motor scores improved. But again: not randomized, not placebo-controlled, and the published abstract doesn't give effect sizes, confidence intervals, or p-values.

There's a separate strand on inflammation. Russian clinical work in acute stroke patients reports that Semax shifts the cytokine balance, with IL-10 up and IL-8 and CRP down. The mechanism is consistent with melanocortin biology, where melanocortin-receptor agonists generally exert anti-inflammatory effects. Whether the magnitude of shift translates to meaningful clinical benefit in stroke recovery is exactly what a real RCT would tell us, and exactly what hasn't been run.

Romanova's 2006 rat photoinduced ischemia work showed dose-dependent reductions in cortical infarction volume and preserved memory function after six days of intranasal Semax ^[8]. Strong animal data. Replicated where? Mostly within the same Russian research network.

The pattern repeats across the literature. Internal consistency is reasonable. Independent external replication is essentially absent.

For healthy people using Semax to enhance cognition, the evidence base is much thinner than vendor marketing suggests.

There's one functional MRI study (Lebedeva et al., 2018) reporting measurable changes in default mode network activity in human subjects after Semax administration ^[9]. Default mode network changes are interesting and not the same thing as performance improvement on a cognitive task. The study is small and not, to our knowledge, independently replicated.

Animal learning studies are more numerous. Conditioned passive avoidance improves with intranasal Semax. Rats remember things better. The leap from "rats remember things better" to "this will make a 32-year-old software engineer think more clearly" is the leap nootropic marketing routinely makes without paying for the airfare.

The Alzheimer's Drug Discovery Foundation reviewed Semax for cognitive enhancement in healthy people and for Alzheimer's. Their conclusion: evidence is insufficient to recommend it for either use ^[10]. The Biomeme Evidence Score puts Semax at 29/100, with human trial evidence at 8/25 and safety profile at 5/25 ^[11], not because the molecule is dangerous, but because the data to confirm safety aren't there.

That doesn't mean it doesn't work. It means nobody has run the trial that would tell you whether it works, in whom, at what dose, for what kind of cognitive task. User reports on r/Nootropics and elsewhere skew positive, which is what user reports for any psychoactive substance always skew. Selection bias does a lot of heavy lifting in those threads.

The anxiolytic claim is largely user-driven. People report feeling calmer and less reactive, particularly during stressful work periods.

The mechanistic backing exists in fragments. Serotonin modulation, dopaminergic potentiation, and melanocortin signaling are all plausibly involved in mood and anxiety. A 2021 rat study (PMID 33418449) showed Semax attenuated behavioral and neurochemical alterations following neonatal fluvoxamine exposure ^[12], which is a specific finding in a specific developmental model and not a general endorsement of anxiolytic activity.

What's missing: a placebo-controlled human anxiety trial. We don't have one. The mood effects users describe might be real, might be placebo amplified by a $200/year peptide habit, or might be displacement of attention onto a novel routine. The honest answer is that nobody knows, and anyone who claims to know is selling something.

Three forms circulate in the research-peptide market, and the differences are pharmacokinetic rather than pharmacological.

Standard Semax is the original peptide. Effects are reported to last a few hours. Russian clinical protocols use it because it's what the trials were run with.

N-Acetyl Semax adds an acetyl group to the N-terminus, protecting against aminopeptidase degradation. Semax Amidate adds an amide to the C-terminus, protecting against carboxypeptidase degradation. Combine both modifications and you get N-Acetyl Semax Amidate, the form most common in current US research-peptide commerce. Duration of effect runs several hours.

A third variant called Adamax, with additional structural modifications, is sometimes marketed as longer-acting and more potent. It's also the least studied of the three. The studies underlying Russian regulatory approval used standard Semax. Generalizing safety and efficacy data to modified variants involves an assumption, that the pharmacodynamic profile carries over with only the pharmacokinetic profile changing, that has not been formally tested.

Practical reality: most US users default to N-Acetyl Semax Amidate because it requires fewer daily doses. Whether the efficacy profile matches the clinical-trial form remains an open question.

Intranasal is the route Russian clinical protocols use and the route the BDNF data come from. The reason is anatomy: the olfactory nerve provides a partial bypass around the blood-brain barrier, allowing peptide molecules to reach the CNS without first being degraded by liver enzymes or filtered out of systemic circulation.

Subcutaneous injection is used in some research and clinical settings, particularly where consistent systemic exposure matters more than peak CNS concentration. The peptide reaches the brain, but the route is less efficient for CNS-specific effects.

Oral administration is essentially useless. Peptides are dismantled by digestive enzymes before absorption, which is why no Semax tablet exists.

A practical note: animal research has found that intranasal Semax produced learning improvements that intraperitoneal Semax did not, while the intraperitoneal route produced analgesic effects the intranasal route did not. Different brain regions, different routes of entry, different pharmacodynamic profiles. The choice of route shapes the effect.

Russian clinical protocols cluster in two ranges. Stroke recovery and acute neurological indications use 6,000 to 18,000 mcg/day, typically delivered as a 1% nasal spray over five to ten days, sometimes in two ten-day courses separated by a twenty-day washout ^[13].

Cognitive and self-experimentation dosing is much lower. The range reported in literature and user reports typically involves the 0.1% nasal spray formulation, with doses administered as a small number of drops per nostril one or more times daily. Cycles of days to weeks are common; continuous long-term dosing is uncommon and unstudied.

The gap between research-grade clinical doses and self-experimentation doses is roughly tenfold. The clinical doses target acute neurological injury where the goal is maximum neurotrophic stimulation. The lower doses target subtle cognitive modulation in an otherwise healthy brain. Whether the lower doses do anything mechanistically meaningful is, again, not something we have human trial data to answer.

There's no established safe long-term dosing regimen. The longest published clinical exposure is the two ten-day courses in the Gusev 2018 trial. Anything beyond that runs on extrapolation.

The reported adverse event profile is mild. The most common complaint in Russian clinical literature is nasal irritation: burning, congestion, runny nose, sometimes discoloration of the nasal mucosa. A minority of patients in Kolomin's 2013 review experienced this. Transient headache and mild fatigue are also reported.

A more clinically meaningful flag: some reports suggest diabetic patients may experience blood glucose elevation on Semax. The mechanism isn't fully worked out, but anyone with diabetes considering Semax should know this and monitor accordingly.

User reports add insomnia (predictable for an alerting compound; mitigated by morning dosing), occasional irritability, nausea, dizziness, and appetite variation. Nothing on the list rises to the level of serious adverse event in the published literature.

What we don't know is more important than what we do.

Long-term safety data are absent. The longest studied human exposure is weeks, not months or years. We have no independent Western pharmacovigilance. The FAERS database returns hits that are likely from unrelated drug queries. Semax doesn't have meaningful FAERS attribution because it's not an FDA-regulated product in the US. People taking Semax for years are doing so in an evidence vacuum.

Special-population data are also missing. Pregnancy and breastfeeding are not studied, and defaulting to "not recommended" is the prudent move. Seizure disorders deserve caution. Active psychiatric conditions and concurrent psychoactive medications deserve a conversation with a prescriber, especially given the serotonergic and dopaminergic modulation. Adrenal or pituitary pathology raises theoretical concerns given the ACTH lineage of the molecule, even though Semax is engineered to lack steroidogenic activity.

The honest framing: no serious adverse events have been documented at standard doses in published trials. That's not the same as confirmed long-term safety. The absence of evidence of harm is not evidence of absence of harm.

Russia registered Semax as a prescription medication in 1994 ^[14]. It sits on the Russian List of Vital and Essential Drugs, periodically updated by government decree. Reported approved indications span acute ischemic stroke, transient ischemic attack, cognitive and memory disorders, encephalopathy, optic nerve atrophy, and related conditions, though English-language primary documentation of the Russian registration is limited ^[15]. Ukraine has reportedly approved it for related neurological indications. It falls within a catch-all category for other psychostimulants and nootropics.

In the United States: nothing. Semax has not been evaluated, approved, or marketed by the FDA for any indication. It's unscheduled, not a controlled substance, which means it's not illegal to possess, but it's also not legal to market or sell for human therapeutic use. The standard workaround is "research chemical" labeling, which puts the molecule in a gray zone where vendors sell it, buyers use it, and nobody is technically supposed to consume it.

Compounding pharmacy access is also gray, and it moved in 2026. Semax was one of twelve peptides FDA removed from Category 2 of its 503A interim policy on April 15, 2026, and on July 24 the agency's Pharmacy Compounding Advisory Committee voted to recommend it for the 503A bulks list — 8 in favour, 5 against, 1 abstention, free base and acetate voted separately with the same outcome ^[16]. The uses FDA had evaluated were cerebral ischemia, migraine and trigeminal neuralgia, and the agency's own reviewers had proposed rejecting it.

That is a recommendation, not a rule. It is non-binding, FDA has issued no final determination, and Semax is still not on the 503A positive list — which is the only thing that would make it legally compoundable, and which requires rulemaking that has not started. Our report on the vote has the record. Some pharmacies have prepared Semax under 503A patient-specific rules in some states, but the regulatory basis for that was uncertain before the vote and remains uncertain after it.

WADA does not currently include Semax on its Prohibited List. Athletes should verify with their specific governing body, because the absence of a substance from one list doesn't guarantee absence from sport-specific rules.

Why the regulatory gap? Mostly because nobody with the resources to run a US clinical trial program has done so. The intellectual property is old. The Russian clinical data are not in a format the FDA accepts. The commercial incentive to spend tens of millions of dollars getting an unpatented peptide approved is essentially zero. The drug exists in regulatory limbo not because of safety concerns but because of economics.

Here's what a researcher actually needs to know about the evidence base.

Almost every human study is Russian. Many are published in Zhurnal Nevrologii i Psikhiatrii and exist in English only as abstracts. The trials are generally non-randomized, often without placebo controls, and frequently lack the effect sizes, confidence intervals, and p-values that Western evidence appraisal requires.

The mechanism story is mostly animal data. BDNF upregulation in rat hippocampus, monoamine modulation in rat striatum, ischemia protection in rat cortex. The bridge from rodent to human pharmacodynamics, particularly at the doses humans actually take, is built on inference.

The cognitive enhancement claims for healthy people have the thinnest support. The Alzheimer's Drug Discovery Foundation reviewed the literature and concluded the evidence doesn't support recommending Semax for cognitive enhancement. User reports are positive but vulnerable to placebo and selection bias.

The variant forms (N-Acetyl Semax, Semax Amidate, Adamax) are pharmacokinetically interesting and pharmacodynamically understudied. The clinical-trial data don't necessarily transfer.

Long-term safety is genuinely unknown. The longest human exposure in published data is weeks. People dosing for years are operating in evidence-free territory.

And the gap between Russian clinical use and Western regulatory engagement is not a sign that one side is right and the other is wrong. It's a sign that two scientific cultures have evaluated the same molecule against different standards of evidence, with different commercial incentives, and reached different conclusions about what counts as sufficient proof.

Semax may turn out to be a meaningful neuroprotective tool. The plausibility is there. So is the BDNF data. So is thirty years of Russian clinical use without obvious safety disasters. What's missing is the trial that would let an FDA reviewer, or a careful patient, or an evidence-based clinician, actually know.

That gap is unlikely to close soon. Researchers working with Semax should plan accordingly.